---
document_datetime: 2024-10-25 12:39:27
document_pages: 18
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/oncaspar-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: oncaspar-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 10.8478757
conversion_datetime: 2025-12-19 23:55:50.188921
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Oncaspar

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                 |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------|
| IB/0055              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 23/10/2024                          | n/a                                         |                                  |                                                                         |
| II/0053/G            | This was an application for a group of variations.                                                                                            | 16/05/2024                          |                                             | SmPC and PL                      | SmPC new text: Hepatic veno-occlusive disease (VOD) , including severe, |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | - Type II (C.I.4): Update of sections 4.4 and 4.8 of the SmPC in order to add 'Hepatic veno-occlusive disease (VOD)' as a warning and new safety risk with 'not known' frequency, following an internal signal evaluation. The Package Leaflet is updated accordingly. - Type IB (C.I.3.z): Update of sections 4.4 and 4.8 of the SmPC in order to add 'Antithrombin III decreased' to the list of adverse drug reactions with frequency 'Very common' and to update the frequency of 'Neutrophil count decreased' from 'Not known' to 'Very common', following the outcome of the PAM procedure P46/008. The Package Leaflet is updated accordingly. C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |     | life-threatening and potentially fatal cases have been observed in patients treated with Oncaspar in combination with standard chemotherapy, including during the induction phase of multiphase chemotherapy (see section 4.8). Signs and symptoms of VOD include rapid weight gain, fluid retention with ascites, hepatomegaly, thrombocytopenia and rapid increase of bilirubin. The identification of risk factors like pre-existing liver disease or history of VOD is essential for its prevention. Prompt recognition and appropriate management of VOD remain imperative. Patients who experience this condition should be treated according to standard medical practice. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0052/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22/06/2023 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                     | starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10457 /202207 | Periodic Safety Update EU Single assessment - pegaspargase (centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                                      | 16/03/2023 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0051             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                  | 23/01/2023 | 11/01/2024 | Annex II    |                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0048             | Update of sections 4.2 and 4.4 of the SmPC in order to add advice on premedication to reduce the cases of hypersensitivity reactions based on literature review and guidelines. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                  | 21/07/2022 | 13/09/2022 | SmPC and PL | In order to decrease the risk and severity of infusion and hypersensitivity reactions, patients should be premedicated with paracetamol, an H-1 receptor blocker, and an H-2 receptor 30-60 minutes prior to administration of Oncaspar patients should be premedicated with paracetamol, an H-1 receptor blocker, and an H-2 receptor blocker. For more information, please refer to the Summary of Product Characteristics. |
| IB/0049/G           | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 08/09/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| IB/0047   | C.I.7.a - Deletion of - a pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 02/06/2022   | 24/06/2022   | SmPC, Labelling and PL   |                        |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|------------------------|
| II/0045/G | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS A.7 - Administrative change - Deletion of manufacturing sites B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of | 05/05/2022   | n/a          |                          | an obsolete parameter) |
| IB/0046/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - quality control testing arrangements for                                                                                                                    | 25/04/2022   | n/a          |                          | Changes to             |

<div style=\"page-break-after: always\"></div>

|           | batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0038   | Update of sections 4.4, 4.5 and 4.8, of the SmPC in order to add a new warning on the risk of osteonecrosis and to include it as an adverse drug reaction associated with pegaspargase use with an unknown frequency, following review of all available non-clinical, epidemiological and clinical data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 13/01/2022 | 24/06/2022 | SmPC and PL | Pegaspargase may increase the risk of glucocorticoid- induced osteonecrosis in children and adolescents with a higher incidence seen in girls. Therefore, when pegaspargase is co-administered with glucorticoids a close monitoring in children and adolescents' patients is recommended in order to detect any clinical signs/symptoms of osteonecrosis. For more information, please refer to the Summary of Product Characteristics. |
| IB/0044   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 20/12/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0042   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                          | 01/10/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0043   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 01/09/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0041/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 29/07/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|             | and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                      |            |            |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0040/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                        | 05/05/2021 | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0039/G   | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method | 22/03/2021 | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0036/G   | This was an application for a group of variations. Group of 2 Type II variations to submit (1) the final study results of Study 12-266 A(12), an open label single arm phase II trial evaluating the efficacy and toxicity of treatment regimens including Oncaspar in adults (aged 18-60) with newly diagnosed Philadelphia chromosome-negative acute                                                                          | 11/02/2021 | 24/06/2022 | SmPC and Annex II | The following obligation has been fulfilled, and therefore it is recommended that it be deleted from the Annex II: - Study 12-266 A(12): 'Post-authorisation efficacy study (PAES): In order to further define the efficacy and safety of Oncaspar in adult patients with acute lymphoblastic leukaemia, the MAH should submit the results of a multicentre, open label single arm phase II trial evaluating the efficacy and toxicity of treatment regimens |

<div style=\"page-break-after: always\"></div>

|           | lymphoblastic leukaemia and (2) interim results of Study CAALL-F01, a prospective multicentre cohort study evaluating Oncaspar used in the first-line treatment of children and adolescents with ALL along with multi-agent chemotherapy. Consequently, Annex II updated to remove Study 12-266 A(12). The RMP (version 4.1) is updated accordingly. An editorial change has been added to the SmPC. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH   |            |     | including Oncaspar in adults (aged 18-60) with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukaemia.'   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------|
| IB/0037/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 25/11/2020 | n/a |                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| R/0034    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 17/09/2020   | 20/11/2020   | SmPC and PL   |                       |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-----------------------|
| II/0035   | B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 03/09/2020   | n/a          |               |                       |
| IB/0032/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an already authorised | 02/07/2020   | n/a          |               | alternative method is |

<div style=\"page-break-after: always\"></div>

| PSUSA/10457 /201907   | Periodic Safety Update EU Single assessment - pegaspargase (centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 27/02/2020   | 23/04/2020   | SmPC and PL   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10457/201907.   |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0033/G             | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                     | 17/04/2020   | n/a          |               |                                                                                                                                              |
| IA/0031/G             | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits | 17/03/2020   | n/a          |               |                                                                                                                                              |
| IB/0030               | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12/02/2020   | 23/04/2020   | SmPC and PL   |                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IA/0028/G   | was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/09/2019   | n/a   |      |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|------|
|             | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters |              |       | This |

<div style=\"page-break-after: always\"></div>

|                     | material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)   |            |            |                 |                                                                                                                                            |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0027/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                   | 13/09/2019 | n/a        |                 |                                                                                                                                            |
| IB/0026             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                         | 23/07/2019 | 09/03/2020 | Annex II        |                                                                                                                                            |
| PSUSA/10457 /201807 | Periodic Safety Update EU Single assessment - pegaspargase (centrally authorised product)                                                                                                                                                                                                                             | 28/02/2019 | 26/04/2019 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10457/201807. |
| IAIN/0025           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                | 29/03/2019 | 09/03/2020 | Annex II and PL |                                                                                                                                            |
| IB/0024             | C.I.11.z - Introduction of, or change(s) to, the                                                                                                                                                                                                                                                                      | 25/03/2019 | 09/03/2020 | Annex II        |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| T/0021    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 19/10/2018 | 10/12/2018 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IAIN/0023 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 06/12/2018 | 26/04/2019 | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0016/G | This was an application for a group of variations. Update of sections 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC based on the final results from studies DFCI 11-001 and AALL07P4 listed as category 3 studies in the Risk Management Plan: Study DFCI 11-001 is a Phase 2, open-label, randomized, multicenter study to determine the safety and feasibility of administering an investigational asparaginase product (asparaginase formulation) compared with Oncaspar in subjects aged 1 to <22 years with newly diagnosed Acute Lymphoblastic Leukaemia (ALL) and lymphoblastic lymphoma. Study AALL07P4 is a multicenter, open label, randomized, active-controlled, parallel design clinical pilot study conducted to evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity and efficacy of an investigational | 04/10/2018 | 10/12/2018 | SmPC and PL            | The pharmacodynamic effect of Oncaspar was assessed after IM (Study CCG 1962) and IV administration (AALL07P4). Based on results from these two studies, a 2,500 U/m2 BSA dose of Oncaspar administered IM (CCG 1962) and IV (AALL07P4) provides maintenance of L asparagine depletion for approximately two weeks following dosing. The results on pharmacokinetic properties were reflected in section 5.2. Overall, results indicate that, when Oncaspar 2,500 U/m2 BSA is administered as single and repeated doses every two weeks, clinically relevant asparaginase activity is sustained over the entire dosing interval (i.e. two weeks). Results from Study CCG-1962 from the initial application were also reflected. The controlled studies were not designed to formally evaluate the pharmacokinetics of Oncaspar in specific populations. A population pharmacokinetic evaluation of Oncaspar based on data obtained from Studies AALL07P4 (IV), DFCI 11 001 (IV), and CCG 1962 (IM) identified that clearance (linear and saturable) increased approximately proportional to BSA |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| comparison with Oncaspar in patients aged 1 to <31 years newly diagnosed with high risk B-precursor ALL. The Package Leaflet has been updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | asparaginase product in   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     | products can result in severe hepatic toxicity and those patients should be monitored for changes in liver function parameters. Due to the risk of hyperbilirubinaemia, it is recommended to monitor bilirubin levels at baseline and prior to each dose, whereas ammonia levels should be monitored closely in case of hyperammonaemia symptoms (nausea, vomiting, headache, dizziness and rash). Warning was reviewed to clearly indicate that Oncaspar may also cause myelosuppression and therefore increase the risk of infections. It is strongly recommended that every time Oncaspar is administered to a patient, the name and lot number of the product are recorded in order to link the patient and the lot of the product and thereby closely monitor patients for any adverse reactions throughout the administration period.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0019/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 27/07/2018 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PSUSA/10457 /201801 | Periodic Safety Update EU Single assessment - pegaspargase (centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                      | 12/07/2018 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IA/0018             | B.I.b.1.d - Change in the specification parameters                                                                                                                                                                                                                                                                                                                                                                                                             | 02/05/2018 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                     | and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                    |            |            |                                  |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| IB/0014/G           | This was an application for a group of variations. B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product B.II.f.1.e - Stability of FP - Change to an approved stability protocol | 27/03/2018 | 10/12/2018 | SmPC, Labelling and PL           |                                   |
| IB/0015             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                          | 15/03/2018 | n/a        |                                  |                                   |
| PSUSA/10457 /201707 | Periodic Safety Update EU Single assessment - pegaspargase (centrally authorised product)                                                                                                                                                           | 08/02/2018 | n/a        |                                  | PRAC Recommendation - maintenance |
| X/0008              | Annex I_2.(d) Change or addition of a new pharmaceutical form                                                                                                                                                                                       | 12/10/2017 | 08/12/2017 | SmPC, Annex II, Labelling and PL |                                   |
| IB/0013/G           | This was an application for a group of variations. B.II.b.z - Change in manufacture of the Finished Product - Other variation B.II.f.z - Stability of FP - Other variation                                                                          | 30/11/2017 | n/a        |                                  |                                   |
| PSUSA/10457         | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                       | 01/09/2017 | n/a        |                                  | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| /201701             | pegaspargase (centrally authorised product)                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                                  |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| N/0011              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                      | 19/05/2017 | 08/12/2017 | Labelling and PL                 |                                   |
| IAIN/0010           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                | 12/05/2017 | 08/12/2017 | SmPC, Annex II, Labelling and PL |                                   |
| IA/0007/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 10/02/2017 | n/a        |                                  |                                   |
| PSUSA/10457 /201607 | Periodic Safety Update EU Single assessment - pegaspargase (centrally authorised product)                                                                                                                                                                                                                                                                                                                                                             | 09/02/2017 | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0006             | B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation                                                                                                                                                                                                                                                                                                                                               | 02/02/2017 | n/a        |                                  |                                   |
| IA/0003             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other                                                                                                                                                                                                                                                                                                                                            | 22/06/2016 | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

|         | variation                                                                                                                              |            |            |    |
|---------|----------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|
| N/0002  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                       | 29/04/2016 | 08/12/2017 | PL |
| IB/0001 | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 07/03/2016 | n/a        |    |